Item 1(a). | Name of Issuer: |
Sophia Genetics SA (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
Item 2(a). | Name of Person Filing: |
This joint statement on Schedule 13G is being filed by Balderton Capital VI, S.L.P. (“BCVI”) and Balderton Capital General Partner VI, S.á.r.l. (“BCVI Sarl” and together with BCVI, the “Reporting Persons”).
Item 2(b) | Address of Principal Business Office, or if None, Residence: |
The address of the principal business office of each Reporting Person is 3, Rue Gabriel Lippmann, L- 5365 Munsbach, Luxembourg.
BCVI is a Luxembourg special limited partnership. BCVI Sarl is a Luxembourg private limited liability company.
Item 2(d). | Title of Class of Securities: |
Ordinary Shares, CHF 0.05 per share (the “Ordinary Shares”)
H82027105
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| (a) | Amount beneficially owned: |
See Row 9 of the cover page for each Reporting Person. BCVI is the record owner of the 3,361,880 Ordinary Shares (the “BCVI Shares”). As the managing general partner of BCVI, BCVI Sarl may be deemed to beneficially own the BCVI Shares. Adrian Rainey, Donatien-Xavier Martin and Marie Calinet (the “Managers”) are the managers of BCVI Sarl and, as the managers of BCVI Sarl, each of the Managers also may be deemed to beneficially own the BCVI Shares , however such Managers disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein, if any.
See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*